/ Print /

  • linkedin
  • Increase Font
  • Sharebar

    Opportunities to Improve Glaucoma Treatment


    The goal of most glaucoma treatments is to lower eye pressure more effectively or more safely for longer periods of time.

    A new molecular class of drugs, rho kinase (ROCK) inhibitors, is in development for the treatment of glaucoma patients. With minimal systemic side effects and tolerable ocular side effects, ROCK inhibitors have no contraindications — thus offering doctors and patients a necessary treatment option with convenient, once-a-day dosing.

    Learn more about how this class fits into the timeline of advances in glaucoma treatment, and the potential that ROCK inhibitors may hold.

    Read the Whitepaper now




    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available